Immunotherapy Market value, page-35

https://www.google.com/url?sa=t&source=web&cd=12&ved=2ahUKEwiTpruJxtbgAhUYbn0KHSovAHIQFjALegQIARAB&url=https%3A%2F%2Fwww.sciencedaily.com%2Freleases%2F2017%2F05%2F170504185213.htm&usg=AOvVaw30svkIcVISK8fVYhJDEqtN


More to come from me on this, but basically if keytruda can get to some
white blood cells (monocytes) it has a good chance of success, but it
can't get to them all, hence the circa 45-50% success rate.......The remaining
55-50% require some sort of stimulus to become available to the checkpoint
inhibitors......This is where "EFTI" comes in, if it can stimulate the dormant
(for want of a better word) white cells so that keytruda can get to them and
keytruda and "EFTI" can work together it's exciting times for us......

please don't take this as gospel, it's my understanding and I'm a construction
worker with no medical knowledge...